GoodRx Holdings Inc（GDRX）资讯与事件GDRXGoodRx Holdings Inc

GoodRx Q2 Revenue $200.4M, Exceeds Consensus

Reports Q2 revenue $200.4M, consensus $193.16M. "We entered 2026 focused on scaling Pharma Direct and subscriptions, and the second quarter provided clear evidence that those investments are translating into stronger performance," said Wendy Barnes, President and Chief Executive Officer of GoodRx. "We believe this progress is accelerating our return to growth and strengthening the long-term durability of GoodRx."

Raises FY26 Adjusted EBITDA Outlook to $240M-$250M

Consensus $775.88M. Raises FY26 adjusted EBITDA view to $240M-$250M from over $235M.

GoodRx Launches GoodRx Companion Subscription at $14.99 per Month

GoodRx launched GoodRx Companion, a new $14.99-per-month subscription. "GoodRx Companion is an important step in our evolution toward building a broader subscription model built for the way consumers are navigating healthcare today," said Wendy Barnes, President and CEO of GoodRx. "As coverage becomes more complex and out-of-pocket costs continue to rise, people are looking for trusted solutions that give them greater control and clearer value. Companion meets that demand while advancing our strategy to build deeper, more recurring consumer relationships across a growing portfolio of subscription offerings. This is where we believe the market is headed, and where we believe GoodRx is uniquely positioned to lead."